Arrhythmias & electrophysiologyRandomised controlled trial
Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation
- Randomised controlled trial
- abelacimab blinded, rivaroxaban open-label
- stopped early
Authors' conclusion
Among patients with atrial fibrillation who were at moderate-to-high risk for stroke, treatment with abelacimab resulted in markedly lower levels of free factor XI and fewer bleeding events than treatment with rivaroxaban.
Study context
- Population
- Patients with AF and moderate-to-high risk of stroke
- Participants
- 1,287 patients
- Comparison
- Abelacimab vs rivaroxaban
- Primary endpoint
- Major or clinically relevant nonmajor bleeding
Primary result
As reported in the abstract
Each group vs rivaroxabanHazard ratio (95% CI)P value
Abelacimab 150 mg
0.38(0.24–0.60)
P < 0.001Abelacimab 90 mg
0.31(0.19–0.51)
P < 0.001Further findings
Median
| Outcome | Abelacimab 150 mg | Abelacimab 90 mg | Rivaroxaban |
|---|---|---|---|
| Reduction in free factor XI levels · 3 months | 99% (IQR 98–99) | 97% (IQR 51–99) | Not reported in the abstract |
Safety
Adverse events (incidence and severity)
- Appeared similar in the three groups
Original publication
Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation. N Engl J Med. Published 23 January 2025. doi:10.1056/nejmoa2406674
Summarised from the published abstract; every number is checked against it